ATE62254T1 - Multispezifische immunogene proteine. - Google Patents

Multispezifische immunogene proteine.

Info

Publication number
ATE62254T1
ATE62254T1 AT85305989T AT85305989T ATE62254T1 AT E62254 T1 ATE62254 T1 AT E62254T1 AT 85305989 T AT85305989 T AT 85305989T AT 85305989 T AT85305989 T AT 85305989T AT E62254 T1 ATE62254 T1 AT E62254T1
Authority
AT
Austria
Prior art keywords
protein
hapten
molecular weight
aggregating
self
Prior art date
Application number
AT85305989T
Other languages
English (en)
Inventor
Eric A James
Robert T Garvin
Joel R Haynes
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Application granted granted Critical
Publication of ATE62254T1 publication Critical patent/ATE62254T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT85305989T 1984-08-22 1985-08-22 Multispezifische immunogene proteine. ATE62254T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848421282A GB8421282D0 (en) 1984-08-22 1984-08-22 Multispecific antigenic proteins
EP85305989A EP0174759B1 (de) 1984-08-22 1985-08-22 Multispezifische immunogene Proteine

Publications (1)

Publication Number Publication Date
ATE62254T1 true ATE62254T1 (de) 1991-04-15

Family

ID=10565652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85305989T ATE62254T1 (de) 1984-08-22 1985-08-22 Multispezifische immunogene proteine.

Country Status (7)

Country Link
US (1) US5972659A (de)
EP (1) EP0174759B1 (de)
JP (1) JP2528815B2 (de)
AT (1) ATE62254T1 (de)
CA (1) CA1340776C (de)
DE (1) DE3582380D1 (de)
GB (1) GB8421282D0 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
EP0264150B1 (de) * 1986-10-13 1993-01-07 Solvay Mikroorganismen, die fremdproteinenthaltende Pili tragen, isolierte Pili, Verfahren zur Ausscheidung von Proteinen in Verwendung dieser Pili und deren Nutzen
ZA88488B (en) * 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
US6660500B2 (en) 1988-02-26 2003-12-09 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
US7033835B1 (en) 1988-02-26 2006-04-25 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
GB9108386D0 (en) 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
AU5838794A (en) * 1993-01-16 1994-08-15 British Bio-Technology Limited Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens
JP2688879B2 (ja) * 1994-02-08 1997-12-10 騏一 小林 切断器
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
CA2202761A1 (en) 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
EP1280520B2 (de) 2000-05-10 2018-03-21 Novartis AG Pulver auf basis von phospholipiden zur wirkstoffverabreichung
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
CU23002A1 (es) 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
CA3173307A1 (en) * 2020-05-04 2021-11-11 Hexamer Therapeutics, Inc. Vaccines against viral pathogens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006553A1 (de) * 1978-07-03 1980-01-09 International Business Machines Corporation Verfahren und Vorrichtung zum Betrieb einer Heizquelle in einem Kopiergerät
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
CA1192510A (en) * 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
WO1988003950A1 (fr) * 1982-11-30 1988-06-02 Marc Girard PEPTIDES COMPORTANT UN SITE IMMUNOGENE DU POLIOVIRUS ET ADNs CONTENANT DES SEQUENCES NUCLEOTIDIQUES CODANT POUR CES PEPTIDES
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5316931A (en) * 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes

Also Published As

Publication number Publication date
GB8421282D0 (en) 1984-09-26
JPS61143327A (ja) 1986-07-01
EP0174759B1 (de) 1991-04-03
CA1340776C (en) 1999-10-05
US5972659A (en) 1999-10-26
EP0174759A1 (de) 1986-03-19
DE3582380D1 (de) 1991-05-08
JP2528815B2 (ja) 1996-08-28

Similar Documents

Publication Publication Date Title
ATE62254T1 (de) Multispezifische immunogene proteine.
EP0154902A3 (en) Pre-s gene coded peptide hepatitis b immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
ATE207535T1 (de) Hepatitis-b-oberflächenantigen enthaltendes peptid
EP0243913A3 (de) Pre-S Gen codierte peptidische Hepatitis B Immunogene, Impfstoffe, Diagnosemittel und synthetische Lipid Transportvesikel
NO872988D0 (no) Pattedyr-interleukin-4.
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
ES2109217T3 (es) Determinante peptidico asociado con la inmunidad.
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
EP0193585A4 (de) Kreuzreaktive und schützende epitope von circumsporozoit-proteinen.
EP0293827A3 (de) Probe für Leishmaniosis
EP0414816A4 (en) Induction of tolerance to a foreign antigen
GR1000321B (el) Ανασυνδυασμενες διαλυτες πρωτεινες για την μεταβολη της ορμονικ σ εκκρισεως.
AU532186B2 (en) Herpes virus vaccine
AU7145087A (en) Tumor-associated antigens (mol wt 160,000-170,000; 44,000-46,000; 29,000-35,000)
IL108419A (en) Proteinaceous extract derived from eimeria maxima gametocytes and vaccines against eimeria maxima containing the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time